Medina D L, Settembre C, Ballabio A
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples, Italy.
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples, Italy; Dulbecco Telethon Institute (DTI), Naples, Italy; Medical Genetics, Federico II University, Naples, Italy.
Methods Enzymol. 2017;588:61-78. doi: 10.1016/bs.mie.2016.10.008. Epub 2016 Dec 16.
Macroautophagy is a catabolic process deputed to the turnover of intracellular components. Recent studies have revealed that transcriptional regulation is a major mechanism controlling autophagy. Currently, more than 20 transcription factors have been shown to modulate cellular autophagy levels. Among them, the transcription factor EB (TFEB) appears to have the broadest proautophagy role, given its capacity to control the biogenesis of lysosomes and autophagosomes, the two main organelles required for the autophagy pathway. TFEB has attracted major attention owing to its ability to enhance cellular clearance of pathogenic substrates in a variety of animal models of disease, such as lysosomal storage disorders, Parkinson's, Alzheimer's, α1-antitrypsin, obesity as well as others, suggesting that the TFEB pathway represents an extraordinary possibility for future development of innovative therapies. Importantly, the subcellular localization and activity of TFEB are regulated by its phosphorylation status, suggesting that TFEB activity can be pharmacologically targeted. Given the growing list of common and rare diseases in which manipulation of autophagy may be beneficial, in this chapter we describe a set of validated protocols developed to modulate and analyze TFEB-mediated enhancement of autophagy both in vitro and in vivo conditions.
巨自噬是一种负责细胞内成分周转的分解代谢过程。最近的研究表明,转录调控是控制自噬的主要机制。目前,已有20多种转录因子被证明可调节细胞自噬水平。其中,转录因子EB(TFEB)似乎具有最广泛的促自噬作用,因为它能够控制溶酶体和自噬体的生物发生,而这两种细胞器是自噬途径所需的主要细胞器。TFEB因其在多种疾病动物模型中增强细胞对致病性底物的清除能力而备受关注,这些疾病包括溶酶体贮积症、帕金森病、阿尔茨海默病、α1-抗胰蛋白酶缺乏症、肥胖症等,这表明TFEB途径代表了未来创新疗法发展的一种非凡可能性。重要的是,TFEB的亚细胞定位和活性受其磷酸化状态的调节,这表明TFEB的活性可以成为药物作用的靶点。鉴于越来越多的常见和罕见疾病中,调节自噬可能有益,在本章中,我们描述了一套经过验证的方案,用于在体外和体内条件下调节和分析TFEB介导的自噬增强作用。